Compound from mushroom new colorectal cancer therapy, reveals surgery

Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide. In the journal Angewandte Chemie, researchers have reported on the isolation and characterization of a previously unknown class of metabolites (terpene-nonadride heterodimers). One of these compounds effectively kills colorectal cancer cells by attacking the enzyme DCTPP1, which thus may serve as a potential biomarker for colorectal cancer and a therapeutic target.

Rather than using conventional cytostatic drugs, which have many side effects, modern cancer treatment frequently involves targeted tumor therapies directed at specific target molecules in the tumor cells. However, the prognosis for colorectal cancer patients remains grim-there is a need for new targets and novel drugs.

Targeted tumor therapies are mostly based on small molecules from plants, fungi, bacteria, and marine organisms. About half of current cancer medications were developed from natural substances. A team led by Ninghua Tan, Yi Ma, and Zhe Wang at the China Pharmaceutical University (Nanjing, China) chose to use Bipolaris victoriae S27, a fungus that lives on plants, as the starting point in their search for new drugs.

The team first analyzed metabolic products by cultivating the fungus under many different conditions (OSMAC method, one strain, many compounds). They discovered twelve unusual chemical structures belonging to a previously unknown class of compounds: terpene-nonadride heterodimers, molecules made from one terpene and one nonadride unit. Widely found in nature, terpenes are a large group of compounds with very varied carbon frameworks based on isoprene units. Nonadrides are nine-membered carbon rings with maleic anhydride groups. The monomers making up this class of dimers termed “bipoterprides” were also identified and were found to contain additional structural novelties (bicyclic 5/6-nonadrides with carbon rearrangements).

Nine of the bipoterprides were effective against colorectal cancer cells. The most effective was bipoterpride No. 2, which killed tumor cells as effectively as the classic cytostatic drug Cisplatin. In mouse models, it caused tumors to shrink with no toxic side effects.

The team used a variety of methods to analyze the drug’s mechanism: bipoterpride 2 inhibits dCTP-pyrophosphatase 1 (DCTPP1), an enzyme that regulates the cellular nucleotide pool. The heterodimer binds significantly more tightly than each of its individual monomers. The activity of DCTPP1 is elevated in certain types of tumors, promoting the invasion, migration, and proliferation of the cancer cells while also inhibiting programmed cell death. It can also help cancer cells to resist treatment. Bipoterpride 2 inhibits this enzymatic activity and disrupts the-pathologically altered-amino acid metabolism in the tumor cells.

The team was thus able to identify DCTPP1 as a new target for the treatment of colorectal cancer and bipoterprides as new potential drug candidates.

Reference:

Dr. Li Feng, Xinjia Wang, Xinrui Guo, Liyuan Shi, Shihuang Su, Xinjing Li, Dr. Jia Wang, Prof. Ninghua Tan, Prof. Yi Ma, Prof. Zhe Wang, Identification of Novel Target DCTPP1 for Colorectal Cancer Therapy with the Natural Small-Molecule Inhibitors Regulating Metabolic Reprogramming, Angewandte Chemie International Edition, https://doi.org/10.1002/anie.202402543.

Powered by WPeMatico

Mini-PCNL Safe and Effective for Treating Kidney Stones in Children: Study Reveals

Iraq: A recent study published in Urolithiasis Journal has highlighted the safety and efficacy of miniaturized percutaneous nephrolithotomy (mini-PCNL) as a treatment for kidney stones in pediatric patients. This innovative surgical technique offers a minimally invasive option for addressing renal stones, which can cause significant discomfort and complications if left untreated.

The study found that mini-PCNL is safe and achieves a high stone-free rate, making it an appealing choice for patients and healthcare providers.

“In patients with stones larger than 15 mm, the stone-free rate was 87.01%, comparable to the 88.57% observed in adults. Although adults experienced a slightly greater drop in hemoglobin levels, there were no significant differences in complications, including blood transfusions, postoperative fever, or the need for additional interventions,” the researchers wrote.

Mini-PCNL is a refined version of traditional percutaneous nephrolithotomy (PCNL), designed specifically for children. It employs smaller instruments and accesses the kidney through a tiny incision, reducing tissue damage and recovery time. Waleed N. Jaffal, College of Medicine, University of Anbar, Ramadi, Al Anbar, Iraq, and colleagues aimed to evaluate the safety and efficacy of mini-PCNL for treating renal stones in children.

For this purpose, the researchers enrolled 77 patients under the age of 15 with renal stones larger than 15 mm in a prospective case-controlled study conducted at Al-Ramadi Teaching Hospital, Ar Razi Private Hospital, and Ghazi Al-Hariri Hospital for Surgical Specialties in Anbar and Baghdad, Iraq, from January 2020 to January 2024. This group, referred to as group A, was compared to a control group (group B) comprising 70 adult patients aged 18 to 60. Both groups underwent mini-PCNL procedures.

The study compared various factors, including gender, stone size, and location, operation time, stone-free rate, hemoglobin drop, need for blood transfusion, incidence of postoperative fever, any associated visceral injuries, and the requirement for further interventions such as extracorporeal shock wave lithotripsy or flexible ureteroscopy (ESWL or FURS).

The following were the key findings of the study:

  • The ages of patients in group A ranged from 8 months to 15 years, with a mean of 4.30 ± 3.16 years, while group B included adults aged 18 to 60 years, with a mean age of 36.3 ± 12.0 years.
  • There were no significant differences in gender distribution, stone size, or location.
  • The stone-free rate was 87.01% for group A and 88.57% for group B, showing no statistical difference.
  • The average hemoglobin drop was 1.096 ± 0.412 in group A and 1.195 ± 0.110 in group B.
  • Blood transfusions were required in one case from each group, with no significant difference.
  • There were three cases in group A and two in group B needing ESWL, with no statistical difference between the groups.
  • FURS was required in four cases in group A and three in group B.
  • The operative time ranged from 30 to 125 minutes for group A and from 34 to 129 minutes for group B.
  • Postoperative fever occurred in 23 cases in group A and 21 cases in group B (p-value 0.986).
  • Minor liver injuries were reported in one case from each group.

“The findings indicate that mini-PCNL is a safe and effective method for treating renal stones in children, with a low rate of significant complications and a high stone-free rate,” the researchers concluded.

Reference:

Jaffal, W.N., Al-Timimi, H.F.H., Hassan, O.A. et al. The safety and efficacy of miniaturized percutaneous nephrolithotomy in children. Urolithiasis 52, 142 (2024). https://doi.org/10.1007/s00240-024-01643-7

Powered by WPeMatico

Medication and cognitive behavioral therapy can reduce fatigue among MS patients, finds study

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a University of Michigan-led study finds.

The randomized clinical trial compared the effectiveness of modafinil, a wake-promoting medication used to treat sleepiness in people with sleep disorders, and cognitive behavioral therapy, or CBT, on reducing fatigue for over 300 adults with multiple sclerosis whose symptoms interfered with their daily activities.

Overall, investigators found that treatment with either modafinil or CBT alone, which was delivered over the phone, was associated with significant reductions of fatigue over 12 weeks.

A combination of both treatments also worked as well as each individual treatment but did not result in better fatigue scores than the independent interventions.

The findings are published in The Lancet Neurology.

“Fatigue is one of the most common and debilitating symptoms of multiple sclerosis, yet there is still uncertainty about how available treatments should be used or how medication-based treatments compare to behavioral treatments in the real world” said first author Tiffany J. Braley, M.D., M.S., director of the Multiple Sclerosis/Neuroimmunology Division and co-founder of the Multidisciplinary MS Fatigue and Sleep Clinic at University of Michigan Health.

“This research offers new evidence to show that both CBT and modafinil are comparably effective for MS fatigue, which could shape treatment approaches to one of the most challenging symptoms experienced by people with multiple sclerosis.”

Of nearly 3 million people with multiple sclerosis worldwide, up to 90% experience fatigue. Nearly half describe it as their most disabling and impactful symptom.

The research used a real world approach that more closely resembled clinical practice than traditional clinical trials and included stakeholders with MS who helped design the study.

More than 60% of participants in each group of the study reported clinically meaningful improvement in fatigue, which was measured with a survey called the Modified Fatigue Impact Scale.

“These treatments, both individually and as a combination, should be considered as potential options for people with multiple sclerosis with chronic, problematic fatigue,” said senior author Anna L. Kratz, Ph.D., professor of physical medicine and rehabilitation at U-M Medical School.

Braley and Kratz co-led the study, which was funded by the Patient-Centered Outcomes Research Institute.

Collaborators at a secondary study site, the University of Washington, contributed to this pragmatic trial.

“This study focused intently on patient-centered outcomes, and our findings highlight the importance of shared decision making about treatment selection, with consideration of patient characteristics and broader treatment goals,” Braley said.

Trial participants who received only CBT maintained lower fatigue scores at an additional follow-up appointment 12 weeks after the study treatments ended.

CBT has shown robust and durable effects on fatigue in previous research.

“While many people with multiple sclerosis have limited access to behavioral health care like CBT, offering the treatment through telehealth can help reach more patients,” Kratz said.

“Our study shows that CBT is a feasible treatment that teaches fatigue management skills that can be employed indefinitely, with enduring benefits that last well beyond the treatment period.”

Although the three treatment assignments worked similarly well overall, participants’ sleep habits, or “sleep hygiene”, affected how well the treatment worked for fatigue.

Those with poor sleep hygiene tended to have better fatigue outcomes with CBT, and participants with very good sleep hygiene showed better fatigue outcomes with modafinil.

“Using wake promoting medications such as modafinil could worsen sleep quality in patients whose sleep problems are behavioral in nature,” Braley said.

“As sleep disturbances also contribute to fatigue in people with MS, it is important to avoid selecting fatigue treatments that could make sleep worse. Behavioral treatments such as CBT that include sleep education may be preferable for people with MS who have poor sleep habits.”

Reference:

Braley, Tiffany J et al., Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial, The Lancet Neurology, DOI:10.1016/S1474-4422(24)00354-5 

Powered by WPeMatico

Benzodiazepine Use in Ischemic Stroke Patients: Decline in Initiation, Yet Excess Supply Persists, Study Reveals

USA: A recent study examining benzodiazepine utilization among ischemic stroke survivors highlights concerning trends in prescription practices. Despite a gradual decline in the initiation of benzodiazepine therapy from 2013 to 2021, researchers found a continued over-prescription of these medications following discharge from acute ischemic stroke care. This situation raises significant questions about the appropriateness of benzodiazepine use in this vulnerable population.

The researchers noted, “Although there was a gradual decrease in the initiation of benzodiazepine prescriptions from 2013 to 2021, the findings revealed an excessive supply of these medications following discharge after an acute ischemic stroke. This situation highlights the urgent need for better prescribing policies.”

The findings were published online on October 17, 2024, in Stroke, the official journal of the American Heart Association (AHA).

Benzodiazepines are commonly prescribed for anxiety, insomnia, and other conditions, but they come with risks, particularly for older adults and those recovering from significant medical events like a stroke. The potential for dependency, increased risk of falls, and cognitive impairment are particularly concerning in stroke survivors, who may already face challenges related to mobility and mental health. While guidelines recommend against prescribing to individuals aged 65 and older, there is limited knowledge about national prescription patterns in this demographic.

To fill this knowledge gap, Julianne D. Brooks, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, and colleagues aimed to analyze the patterns of benzodiazepine prescriptions among ischemic stroke survivors, particularly focusing on the prevalence of excessive supply following discharge and examining longitudinal trends in usage, especially in patients aged 65 and older, where guidelines recommend against such prescriptions.

For this purpose, the researchers analyzed a 20% sample of Medicare claims from April 1, 2013, to September 30, 2021. They focused on beneficiaries aged 65 and older who were discharged alive after an acute ischemic stroke and had traditional Medicare coverage, along with six months of prior enrollment in Parts A (hospital insurance), B (medical insurance), and D (drug coverage).

Individuals with prior benzodiazepine prescriptions, those who self-discharged, or those discharged to skilled nursing facilities were excluded from the study. The researchers analyzed demographics, comorbidities, the duration of initial prescription supplies, and the cumulative incidence of benzodiazepine fills within 90 days after discharge. They also analyzed geographic and yearly trends.

The study led to the following findings:

  • The study included 126,050 beneficiaries with a mean age of 78 years (SD, 8), of whom 54% were female and 82% were White.
  • Within 90 days post-discharge, 6,127 individuals (4.9%) started a benzodiazepine.
  • Among the new prescriptions, lorazepam (40%) and alprazolam (33%) were the most commonly prescribed.
  • Most initial fills (76%) were supplied of more than 7 days, with 55% offering between 15 and 30 days.
  • The initiation rates were higher for females (5.5%) than males (3.8%).
  • Geographically, initiation rates were highest in the Southeast (5.1%) and lowest in the Midwest (4.0%), with a modest decline in nationwide initiation rates from 2013 to 2021 (cumulative incidence difference of 1.6%).

“While the number of new prescriptions decreased over the study period, the total supply of benzodiazepines remained disproportionately high. This discrepancy suggests that many patients continue to receive these medications even when they may not be clinically justified,” the researchers concluded.

Reference:

Lomachinsky Torres V, et al “Benzodiazepine utilization in ischemic stroke survivors: analyzing initial excess supply and longitudinal trends” Stroke 2024; DOI: 10.1161/STROKEAHA.124.047257.

Powered by WPeMatico

Delta neutrophil index promising biomarker for detecting fetal growth restriction processes and its complications, finds study

A study published in the BMC Pregnancy and Childbirth found that the delta neutrophil index is a promising biomarker for detecting fetal growth restriction processes and their complications.

This study investigates the role of Delta Neutrophil Index (DNI), an inflammation marker, in late-onset fetal growth restriction (LO-FGR) and its prediction of composite adverse neonatal outcomes. A retrospective study was conducted on 684 pregnant women (456 with normal fetal development and 228 with LO-FGR) who delivered at Health Sciences University Etlik Zubeyde Hanim Women’s Health Training and Research Hospital between January 1, 2015, and June 30, 2018. Composite adverse neonatal outcomes were defined as at least one of the following: 5th minute APGAR score < 7, respiratory distress syndrome (RDS), or neonatal intensive care unit (NICU) admission. Results: The FGR group had significantly higher levels of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), and DNI compared to controls (p < 0.05, for all). For FGR diagnosis, the DNI demonstrated the highest area under the curve (AUC = 0.677, 95% CI: 0.642–0.711) with a cut-off value of > -2.9, yielding a sensitivity of 78.41%, a specificity of 52.97%, a positive likelihood ratio (+ LR) of 1.68, and a negative likelihood ratio (-LR) of 0.37 (p < 0.001). For predicting composite adverse neonatal outcomes in the FGR group, DNI again demonstrated superior performance with an AUC of 0.635 (95% CI: 0.598–0.670), a cut-off value of > -2.2, a sensitivity of 69.90%, a specificity of 55.36%, a + LR of 1.56, and a -LR of 0.51 (p < 0.001). NLR, PLR, and MLR had AUCs below 0.55, indicating poor discriminative ability, with none reaching statistical significance. This study highlights the potential role of DNI as a promising biomarker for detecting inflammatory processes associated with LO-FGR and its complications.

Reference:

Tonyali, N.V., Sarsmaz, K., Bayraktar, B. et al. Delta neutrophil index (DNI) as a potential biomarker for fetal growth restriction: insights from maternal hematological changes and neonatal outcomes. BMC Pregnancy Childbirth 24, 655 (2024). https://doi.org/10.1186/s12884-024-06853-w

Keywords:

Delta, neutrophil, index, promising, biomarker, detecting, fetal, growth, restriction, processes, its complications, finds, study, BMC Pregnancy and Childbirth, Tonyali, N.V., Sarsmaz, K., Bayraktar, B, Fetal growth restriction, Delta neutrophil index, Neutrophil to lymphocyte ratio, Platelet to lymphocyte ratio, Monocyte to lymphocyte ratio, Perinatal outcomes

Powered by WPeMatico

AIIMS Releases Date Sheet Of DM, MCh Professional Exams December 2024, Details

New Delhi : Through a recent notice, the AIIMS has released the Schedule of Post Graduate/Post Doctoral – DM/MCh Professional Examinations planned to be held in December 2024.

All Candidates are advised to submit their Examination Fees before the last date of Registration (to be announced later) and take a print out of Admit Card form the website, the AIIMS stated in the notice.

No Candidate will be permitted to enter the examination hall without Admit Card and Identity Card. No candidate will be allowed to enter the Examination Hall after the entry time mentioned in the Admit Card, the notice added.

The students must note that the List of Speciality will be published separately.  

I.
THEORY EXAMINATIONS
Date Day Paper
No.
Courses Venue
& Time
03.12.2024 Tuesday I DM/M.Ch Examination
Section Convergence Block, 1st Floor, AIIMS, New Delhi 9:30 AM to 12:30 PM
05.12.2024 Thursday II -do-
07.12.2024 Saturday III -do-
II.
PRACTICAL/ CLINICAL/ VIVA VOCE EXAM
DM/M.Ch Concerned
Department will fix the date, time and venue likely from 10 th December,2024
(Tuesday)to 17 th December,2024 (Tuesday)

Also Read:AIIMS INI SS January 2025: DM, MCh Seats added to AIIMS Bhubaneswar, check details

An Act of Parliament in 1956 established the All India Institute of Medical Sciences (AIIMS) as an autonomous institution of national importance and defined its objectives and functions. By virtue of this Act, the Institute awards its own medical degrees and other academic distinctions. The degrees awarded by the Institute under the All India Institute of Medical Sciences Act are recognized medical qualifications for the purpose of the Indian Medical Council Act and notwithstanding anything contained therein, are deemed to be included in the first schedule of that Act, entitling the holders to the same privileges as those attached to the equivalent awards from the recognized Universities of India.

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/dm-mch-date-sheet-dec-2024-for-net-256193.pdf

Powered by WPeMatico

AstraZeneca gets CDSCO Panel nod to study Budesonide, Glycopyrronium and Formoterol Fumarate

New Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase III clinical study of Budesonide, Glycopyrronium, and Formoterol Fumarate.

This came after the firm presented Phase III clinical study protocol No. : D5989C00001: CSP Version 2.0 dated 28 Jan 2024. Addendum IND-1, Version 1.0, 10 Jan 2024.

This is a randomized, double-blind, parallel-group, multi-center, Phase III study to assess the efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhalers relative to Glycopyrronium and Formoterol Fumarate MDI on cardiopulmonary outcomes in Chronic Obstructive Pulmonary Disease.

Budesonide, glycopyrrolate, and formoterol combination is used as long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This medicine helps improve and reduce the number of flare-ups of the symptoms of COPD.

Inhaled budesonide belongs to the family of medicines known as corticosteroids (cortisone-like medicines). It works by preventing inflammation (swelling) in the lungs that causes an asthma attack.

Glycopyrrolate and formoterol are long-acting bronchodilators. Bronchodilators are medicines that are breathed in through the mouth to open up the bronchial tubes (air passages) in the lungs. They relieve coughing, wheezing, and trouble breathing by increasing the flow of air through the bronchial tubes.

At the recent SEC meeting for pulmonary held on 3rd October 2024, the expert panel reviewed the Phase III clinical study protocol No. : D5989C00001: CSP Version 2.0 dated 28 Jan 2024. Addendum IND-1, Version 1.0, 10 Jan 2024.

After detailed deliberation, the committee recommended a grant of permission to conduct the trial as presented by the firm.

Also Read:Soon, harsher penalties for submitting false data for drug approval

Powered by WPeMatico

No Medical Negligence in Administering Anaesthesia- Consumer Court relief to UP Hospital, Doctors

New Delhi: The National Consumer Disputes Redressal Commission (NCDRC) recently exonerated a UP-based hospital and its two doctors from allegations of medical negligence while administering anaesthesia to a patient before conducting a laparoscopic cholecystectomy.

Even though, the State Commission had directed them to pay a hefty compensation to the patient who lost sensation in her right leg and faced permanent disability, the Apex Consumer Court exonerated them relying on the MRI report and the expert opinion given by SGPGI.

The history of the case goes back to 2014 when the patient suffered sudden abdomen pain and consulted a doctor, who advised for ultrasound of the abdomen and pelvis bone. The report showed “Cholecystitis with echogenic gall bladder sludge. Small left renal concretion”.

When the patient showed the ultrasound report to the treating doctor, he advised certain tests and medication. Thereafter, the patient was admitted to Opal Hospital and the treating doctor conducted the laparoscopic cholecystectomy. It was alleged that after being administered spinal anaesthesia, the patient felt current like shock sensation in her right leg. Immediately, one of the treating doctors took out the needle and inserted it again in the patient’s spine. Against, she felt a current-like sensation. After that, the staff of the hospital held the patient and the doctor inserted the needle for a third time. After administering the anaesthetic medicine, Dr. Rai conducted the surgery. 

However, after regaining consciousness, when the patient tried to move her right leg, she was unable to do so although other body parts were working normally. It was further alleged that despite informing the doctors, they did not pay attention to it. After removing the catheter, the patient realised that there was no sensation in her right leg, which was virtually paralyzed. Consequently, an Orthopaedic Surgeon was called.

Noting that there was no report by the Anaesthetist, the patient’s husband called for the opinion of Dr. Rakesh Singh, a neurosurgeon and Dr. D K Singh, an Anaesthetist. After examining the patient, Dr. Rakesh Singh observed as “(a) Patient not able to walk on 17 Th unable to put right foot properly on ground. (b) O/E not able to dorsiflex right foot. (c) Slight movement on fingers present, sensation on foot absent. (d) Case discussed with orthopaedic surgeon and treatment given as per advice.”

The patient was advised not to walk without any accompanying person to avoid falls. Meanwhile, the treating doctor advised an MRI of the Lumbosacral Spine and the report mentioned, “MRI features of focal increased, Intramedullary signal intensity in the conus meddullar is on T2 weighted images at D12-L1 level as described above. Early Lumbar Spondylosis with mild anterior subluxation of L4 over L5 vertebral body with annular bulge L4/5 I.V. Disc with attendant B/L facet joint arthrosis with hypertrophied ligamentum flavum leading to thecal sac indentation with mild B/l neural foramina encroachment.”

Referring to the MRI report, the complainant argued that the damage to the spinal cord was done while injecting anaesthetic drugs and the damage caused was so severe that could not be reverted back to normal functioning of the right leg.

Despite undergoing treatment for several days, the lack of sensation in the right leg continued and the patient was discharged in that condition. The treating Orthopaedic Surgeon observed “Full right foot drop post spinal. Pain in calf. Tender, mild.”

After this, the patient got herself examined at several other hospitals including IMS, BHU, Max Hospital Delhi, Primus Super Specialty Hospital Delhi, etc. and allegedly she was undergoing treatment even during proceedings before the Consumer Court.

Therefore, alleging that the Anaesthetist was grossly negligent and deficient in administering the spinal anaesthesia to the patient resulting in permanent disability, the plaintiff filed a complaint and prayed for a hefty compensation.

On the other hand, the hospital and doctors denied the allegations and insisted that there was no medical negligence on their part. Referring to the MRI report, they argued that from the report no one can say that the lesion is because of spinal anaesthesia and cannot be reversed back. It was submitted that there was a good response in the patient’s right leg and the patient could put heal on the ground but there was no response in the toe. 

After hearing the parties, the State Commission found that a common rule in the field of anaesthesia was that if you prick the spinal first time and the patient suffers an electric shock, then it must be aborted. Meanwhile, admittedly, the anaesthetist pricked twice and the expert opinion of SPPGI did not mention as to how many times the anaesthetic needle can be pricked if the first prick fails. 

The State Commission had also observed that there was no separate consent for anaesthesia, and the consent form was not in prescribed proforma. Due to defective spinal anaesthesia and lack of knowledge regarding anaesthesia resulted in the pity situation of the patient, which resulted in 60% disability in the patient. Foot drop is a neurological disorder, which occurs following natural childbirth and spinal anaesthesia due to direct needle trauma or local anaesthetic toxicity, the State Commission had noted in its order dated 09.03.2023. It had directed the hospital and the doctors to pay Rs 15 lacs as compensation, Rs 10 as doctor’s fees and other medical expenses, Rs 1 lac for extra nourishment, and Rs 60 lacs for permanent burning, sensation, pain, suffering, disfigurement of right leg, physical and mental agony and litigation cost with interest @10% per annum from 01.01.2019 till the date of payment to the complainant.

This order was challenged by the hospital and the doctors before the Apex Consumer Court, which noted that the patient came to the hospital for laparoscopic cholecystectomy and the patient’s husband signed the Consent Form which was a composite form for operation and anaesthesia. 

“The complainant did not raise any issue in respect of the consent that ‘informed consent’ was not obtained. But State Commission has recorded adverse findings in this respect without there being any issue between the parties in respect,” the NCDRC bench observed.

Referring to Supreme Court orders in the case of Samira Kohli v. Dr. Prabha Manchanda, M.A. Biviji v. Sunita and V. Kishan Rao v. Nikhil Super Speciality Hospital, the top consumer court observed,

“Although, expert opinion is not necessary in every case but expert opinion requires its evaluation cautiously in corroboration of other evidence on record and standard medical literature.”

It was noted by NCDRC that the State Commission ignored the Expert Opinion of SGPGI because it did not mention how many times the anaestheic needle can be pricked if the first prick fails and further did not say about puncturing the spinal nerve during the spinal anaesthesia. The expert did not consider the current-like sensation felt by the patient, it further noted.

Further, the Commission noted that there was no allegation that there was any negligence committed during the surgery of the gall bladder or post-surgery and there was any complication in this regard. The allegations were that the anaesthesia had been administered in a supine condition, the needle was inserted three times, while in first attempt itself and in all attempts, the patient experienced shock-like sensation. The NCDRC bench further noted that the hospital and doctors denied these allegations.

“The spinal anaesthesia cannot be administered in supine condition which is impossibility. Thus the allegation of the complaint in this respect is not liable to be believed. Similarly, the allegation that the patient experienced shock sensation in her right leg in sprinkling the needle has also been denied. The opposite parties stated that the patient was asked to set relaxed in blow down position with head down and in second attempt the anaesthesia has been administered without any help of the other medical staff and there was no complaint about shock sensation in right leg by the patient. OP-3 is an experienced qualified anaesthetist. There is no reason to disbelieve the statement of the OPs in this respect. Similarly presence of OP-3 in operation theatre on 15.02.2014, administering anaesthesia by her are admitted as such there is no reason to disbelieve the records of presurgery assessment of the patient and monitoring the patient during surgery prepared by the OP-3,” the Commission observed at this outset.

While examining the question of whether the complication had been caused due to giving anaesthesia in any wrong or negligent manner, the Commission took note of the MRI report dated 18.02.2014 on record.

“Overall, the MRI findings suggest that the patient has early-stage degenerative changes in her lumbar spine. The mild subluxation, annular bulge, facet joint arthrosis, and ligamentum flavum hypertrophy are all contributing to potential nerve compression. MRI features of focal increased intramedullary signal intensity in the conus medullaris on T2 weighted images at D12-L1 level are often indicative of a pathological process within the spinal cord. Given these MRI findings, nonspecific myelitis is a highly probable diagnosis. This condition involves inflammation of the spinal cord without a clearly identifiable cause. The increased signal intensity on T2-weighted imaging is often a hallmark of inflammation within the spinal cord. The expert of SPPGI has not accepted the allegation of the complainant that these complications developed due to wrong manner of needle prinks. In the absence of any contradictory expert opinion or any standard medical literature, it is not possible to find that OP-3 has committed any medical negligence in administering anaesthesia,” noted the Commission.

“From MRI report no one can say that lesion is because of spinal anaesthesia and cannot be reversed back. There was good response in right leg. The patient could put heel on ground but no response in toe. The patient was feeling better and asked for discharge and she was discharged on 19.02.2014 in morning,” it further noted and accordingly set aside the order of the State Commission.

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/ncdrc-exonerates-257531.pdf

Also Read: Surgeon Cannot be held responsible for gangrene: Consumer Court relief

Powered by WPeMatico

Telangana High Court seeks Report on facilities at State-Run Hospitals

Hyderabad: The Telangana High Court on Thursday ordered a comprehensive report within a week on the facilities available in state-run hospitals across the state.

The directive is followed by the PIL filed by Keethineedi Akhil Sri Guru Teja, president of “Help the People Charitable Trust”. In his PIL he expressed his concern about the lack of medical equipment. The court has directed the Government to provide necessary medical equipment including CT scanners and X-ray machines, telephone connections, blood banks, and the presence of a functional grievance mechanism in all government hospitals.

Also Read: Telangana Govt mulling introducing digitization of peoples’ health profile

In his PIL Guru Teja furtherly expressed concerns about several critical issues affecting healthcare services in Telangana. He expressed concerns about the inadequate facilities and unfilled medical and paramedical staff positions in government hospitals across the region. These deficiencies are not just mere anymore as the petitioners have claimed that it is affecting the healthcare services in the state.

In support of his PIL, Guru Teja submitted the Supreme Court judgment in “Paschim Banga Khet Mazdoor Samity v. State of West Bengal,” which highlights the state’s duty to ensure proper medical facilities for its citizens. The petitioner also referenced the “Indian Public Health Standards, 2022,” emphasizing the need for improved infrastructure and staffing in government hospitals.

As per the New Indian Express reports, during the initial hearing, the Special Government Pleader requested an adjournment to gather instructions and present a detailed report on the current state of facilities in state-run hospitals.

Also Read: Telangana High Court takes suo moto cognizance of rotten dead bodies at Gandhi Hospital morgue

The court recognizing the various issues sought a comprehensive update on various aspects which includes the availability of consultation rooms, number of dialysis units, High-dependency unit (HDU) and intensive care unit (ICU) bed counts, sick newborn care unit (SNCU) and neonatal intensive care unit (NICU) facilities, registration, and drug dispensary counters, nurse-to-patient ratios in hospitals across the state.

The next hearing is scheduled for October 23, 2024, which will be pivotal in determining the future of healthcare in Telangana.

Powered by WPeMatico

Dietary restriction or good genes: New study tries to unpick which has a greater impact on lifespan

As people who research aging like to quip, the best thing you can do to increase how long you live is to pick good parents. After all, it has long been recognized that longer-lived people tend to have longer-lived parents and grandparents, suggesting that genetics influence longevity.

Powered by WPeMatico